Enrollment Completed of the IgA Nephropathy Cohort in the Phase II Clinical Trial of the ETA Receptor Antagonist SC0062

WUXI, China, Feb. 25, 2024. BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials